Decision Aid for Kidney Tumor Patients
This study is testing two ways to help patients with kidney tumors understand their treatment options: a "Decision Aid (DA) Web Tool" and an "Institutional Pamphlet." The web tool offers information, risk communication, and interactive tools to help you assess benefits and harms. The pamphlet provides information but without the interactive features. Researchers want to see if the web tool helps you make more informed decisions and feel more satisfied with your choices. You might be able to join if you are 18 or older, have a localized kidney tumor up to 4 cm, and are having standard care at NYU Urology. The study aims to enroll 40 participants, but its current status is unclear.
- Study design
- This study is interventional and plans to enroll 40 participants. It compares a web tool to a pamphlet to help patients make decisions.
- What's involved
- You would complete assessments of your knowledge, decision satisfaction, and shared decision-making at pre-counseling, post-counseling, and a 1-day visit.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your knowledge, decision satisfaction, and shared decision-making will be measured at a 1-day visit after counseling.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Decision Aid (DA) for Renal Patients
At a glance
Conditions
NCT05387863
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
NYU Langone Health
New York, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Stella Kang, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Knowledge ScorePre-Counsel, 1 day Visit
Via a survey, patients will be asked general questions about kidney masses and their treatments. There are 10 questions, each scored as correct or incorrect (0 or 1), and the last question has 3 sub-components each scored 0-1. The total range of score is 0-10; a score of 10 indicates strongest knowledge on kidney masses/treatments.
- Decision Satisfaction ScorePost-Counsel, 1 day Visit
Via a survey, patients provide their opinion on 16 statements. Each statement is scored 1 (strongly disagree) to 5 (strongly agree). The total range of score is 1-80; a higher score indicates higher satisfaction.
- Shared Decision MakingPost-Counsel, 1 day Visit
This is a binary outcome measure. Patients will be asked whether or not they felt they participated in a shared decision making process: 0 for no, 1 for yes.